BioSpace News Archive

Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that two patients who have undergone heart bypass surgeries utilizing HJLIs CoreoGraft have reached the 30-day milestone and are reported to have good cardiac function.

CereHealth Corp., a data analytics technology company that provides Medical Analytics as a Service announced today the addition of James Chomas, Ph.D. and Ty Vachon, M.D. to their Scientific and Medical Advisory Board.

Cerner Corporation (NASDAQ: CERN), a global health care technology company, today announced an agreement to acquire Kantar Health, a division of Kantar Group, for $375 million in cash, subject to adjustment. Kantar Health is a leading data, analytics and real-world evidence and commercial research consultancy serving the life science industry.

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that data for DANYELZA® (naxitamab-gqgk), omburtamab and nivatrotamab will be presented at the Company’s R&D event, which takes place virtually today at 12 p.m. Eastern Time. Key opinion leaders,

Vertice Pharma, a specialty pharmaceuticals company focused on improving patients’ health, today announced that Sandra Miceli will join the Company as Chief Financial Officer (“CFO”), reporting to Scott Meyers , Chief Executive Officer (“CEO”). Ms. Miceli brings over 25 years of experience in successful pharmaceutical

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an un

- Aditum Bio “spin-out” companies such as Anteris Bio will leverage TrialSpark’s clinical development engine to rapidly advance their drug assets through clinical trials.

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has commenced the first shipments of Combogesic ® to Canadian wholesalers. Combogesic ® is the first fixed-dose combination of acetaminophen and ibuprofen in a single tablet in Canada and is indicated for the short-term management of mild to moderate acute pain and the reduction of fever in adults. Combining two

BIOTRONIK today announced FDA clearance and availability of the Vital Data Sensor, which identifies body temperature increases potentially associated with fever, in the new BIOMONITOR IIIm injectable cardiac monitor (ICM), as shown in a published case report 1 .

Fast-Growing Medical Device Company Developing New Treatment Options for Glaucoma Patients Receives Numerous Awards & Recognition from Ernst & Young, American Academy of Ophthalmology, Red Herring and Others